Melpomeni Kalofonou received the MEng degree in Electrical and Computer Engineering in 2007 from the University of Patras, Greece followed by an MSc in Biomedical Engineering in the Department of Bioengineering in 2009 and a PhD from the Department of Electrical and Electronic Engineering in 2013 as part of the Centre for Bio-Inspired Technology, Imperial College London.
Her PhD research focused on the application of semiconductor technology in detection of cancer biomarkers using microchip based chemical sensors (Ion-Sensitive Field-Effect Transistors, ISFETs) integrated with current-mode circuits as part of Lab-on-Chip diagnostic platforms. Her work led to the demonstration of the first proof-of-concept method using ISFETs for real-time amplification and detection of DNA methylation, an epigenetic biomarker contributing significantly in the development and progression of cancer.
She continued on to become a Postdoctoral Researcher and lead the Cancer Engineering Technology initiative within the Centre for Bio-Inspired Technology. In 2018 she was part of the multidisciplinary team between Electrical Engineering and Medicine which was successful in the Department's first CRUK Multidisciplinary Award. She is now a Research Fellow in Cancer Technology and her current research focuses on the use of fully integrated microchip technology as a diagnostic platform for detection of breast cancer minimal residual disease and relapse as well as monitoring of resistance to treatment, targeting tumour specific cell-free DNA markers through pH-sensitive isothermal DNA amplification chemistries. Her research interests also expand in the development of microchip sensing arrays for detection and quantification of DNA methylation as well as algorithms for feature extraction, classification and prediction based on real-time sensor data for the development of precision medicine systems.
Dr Kalofonou is a member of the IEEE, IEEE-CAS, EMBS, IET, ESMO and has been elected as a member of the Biomedical Circuits and Systems Technical Committee (BioCAS TC).
For more news please follow my twitter @melkalofonou
et al., Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTβR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients, Journal of Clinical Medicine, Vol:8, ISSN:2077-0383, Pages:741-741
Khwaja M, Kalofonou M, Toumazou C, A Deep Autoencoder System for Differentiation of Cancer Types Based on DNA Methylation State, Arxiv Preprint Arxiv:1810.01243
et al., 2018, Adapting ISFETs for Epigenetics: An Overview, Ieee Transactions on Biomedical Circuits and Systems, ISSN:1932-4545
et al., 2019, Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC, American Society of Clinical Oncology, American Society of Clinical Oncology, Pages:8537-8537, ISSN:0732-183X
et al., 2019, 37P Genetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals, European Lung Cancer Congress 2019, Oxford University Press, Annals of Oncology, Pages:mdz073. 016-mdz073. 016